Business

China’s Sinovac gets US$500 million funding boost

Hong Kong’s Sino Biopharmaceutical says it will invest US$515 mil for the development and production of Sinovac’s CoronaVac vaccine candidate

Updated 5 years ago · Published on 07 Dec 2020 5:30PM

China’s Sinovac gets US$500 million funding boost
Sinovac,one of China's leading vaccine producers, says  funding will be used to boost the capacity and manufacture of CoronaVac, one of its most advanced vaccine candidates –  Pixabay pic, December 7, 2020

BEJING – Chinese pharmaceutical firm Sinovac Biotech has secured half a billion dollars in extra funding to produce its Covid-19 vaccine, it said on Monday, as the country races to roll out a jab for general use.

Beijing has largely brought the virus under control, with only 281 active cases still receiving treatment, according to official figures. 

But it has promised to make its vaccines available as a “global public good” as it seeks to counter global criticism for its early handling of the pandemic.

Sino Biopharmaceutical Limited, a Hong Kong-listed medical research firm, said on Monday that it will invest US$515 million for the development and production of CoronaVac, one of Sinovac’s most advanced vaccine candidates. 

Sinovac – one of China's leading vaccine producers –   said the funding will be used for the “further development, capacity expansion and manufacturing” of CoronaVac.

It added it hoped to be able to manufacture 600 million doses by the end of the year.

Sino Biopharmaceutical will receive a 15% share in a Sinovac subsidiary, Sinovac Life Sciences, under the agreement.

Although regulators have yet to approve China’s vaccines for mass distribution, the country has approved some advanced candidates for emergency use. Since July a range of people from state employees to international students have been given jabs.

CoronaVac is being tested in multiple countries including Brazil, where final-stage clinical trials for the jab have restarted after hitting a setback in November when a volunteer experienced an “adverse incident.”

The vaccine “has reached critical milestones in clinical trials in Asia and Latin America,” Sinovac chief executive officer Yin Weidong said in the statement.

The company earlier said almost all its employees and their families have voluntarily taken the vaccine.

Sinopharm, another Chinese vaccine maker, said in November that nearly a million people have already taken its experimental Covid-19 vaccine. 

Last week Britain became the first Western country to approve a vaccine for general use, piling pressure on other countries to follow suit swiftly. – AFP, December 7, 2020

Related News

Malaysia / 2d

Anwar backs One China policy, says Beijing can pursue reunification

Malaysia / 2d

Disturbed woman at KLIA taken to hospital, had forgotten to take medication

Malaysia / 2d

Woman, believed to be foreigner, allegedly causes disturbance at KLIA (video)

Malaysia / 3w

12 officers, police personnel arrested in RM2 million extortion case

Malaysia / 3w

Kedah MB’s “Cina ada China, India ada India” remark draws criticism over citizenship narrative

Tech / 1mth

Penang’s Tech Dome celebrates 10th anniversary with opening of new space gallery

Spotlight

Malaysia

RM245m Penang Hill cable car project 32 per cent complete - CM

By Ian McIntyre

Malaysia

Six locals charged over alleged kidnapping of Singaporean couple in Johor

Malaysia

PM: No political, racial or religious shield for those found guilty in TH, Felda probes

Malaysia

Singapore security guard jailed 14 days, fined RM7,000 for insulting Islam

Health

Dengue cases soar 56% to 58,079 as nation records 55 deaths

Malaysia

NGOs urge BERSAMA to put Indian community agenda on political radar

By Alfian Z.M. Tahir

Health

MOH warns seniors against unproven hydrogen inhalers

Malaysia

Former Tabung Haji CEO remanded seven days as MACC RCI probe deepens

Malaysia

21 held in KLIA-Nilai crackdown on alleged online love scam syndicate

You may be interested

Business

Oil prices hold above US$84 as Middle East tensions persist

Business

FMM urges input tax credits as government reviews GST features for SST

Business

Independent review needed, not blind denial, to address US claims – maritime expert

Business

Tey Por Yee and four others ordered to pay RM103.75m in SC civil suit

Business

Oil prices surge as US-Iran standoff, Ukraine strikes rattle global energy markets

Business

Robo.ai expects shareholders’ equity to turn positive after restructuring

By Alfian Z.M. Tahir